Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Outcomes of Peptide Receptor Radionuclide Therapy with <sup>177</sup>Lu-DOTATATE in Patients with Metastatic Pheochromocytoma and Paraganglioma.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine·2025

Same author

I-131 Uptake in a Benign Diaphragmatic Mesothelial Cyst Mimicking Thyroid Cancer Metastasis on Post-therapy SPECT/CT.

Clinical nuclear medicine·2025

Same author

All that glitters is not gold: high uptake on PSMA PET in non-prostate cancers does not mean that treatment with [<sup>177</sup>Lu]Lu-PSMA-radioligand will be successful.

EJNMMI research·2024

Same author

Clinical Outcomes of Radioactive Iodine Redifferentiation Therapy in Previously Iodine Refractory Differentiated Thyroid Cancers.

Thyroid : official journal of the American Thyroid Association·2023

Same author

123I Scan With Whole-Body Retention Measurement at 48 Hours for Simplified Dosimetry Before 131I Treatment of Metastatic Thyroid Cancer.

Clinical nuclear medicine·2020

Same author

<sup>11</sup>C-Choline PET/CT for Detection and Localization of Parathyroid Adenomas.

AJR. American journal of roentgenology·2017

Search research articles

Related Experiment Video

Updated: Sep 17, 2025

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

Substantial decrease in tumor dose over subsequent cyles of [¹⁷⁷Lu]Lu-PSMA-radioligand treatment

Trond Velde Bogsrud^1,2,3, Jolanta M Durski⁴, Ola Engelsen⁵

¹PET Imaging Center, University Hospital of North Norway, Tromso, Norway. tvbog@aol.com.

European Journal of Nuclear Medicine and Molecular Imaging

|June 30, 2025

Summary

No abstract available in PubMed .

Keywords:

Prostate cancer Targeted radionuclide therapy Theranostic Tumor dosimetry [177Lu]Lu-PSMA-radioligand

More Related Videos

A Whole Body Dosimetry Protocol for Peptide-Receptor Radionuclide Therapy PRRT: 2D Planar Image and Hybrid 2D+3D SPECT/CT Image Methods

A Whole Body Dosimetry Protocol for Peptide-Receptor Radionuclide Therapy PRRT: 2D Planar Image and Hybrid 2D+3D SPECT/CT Image Methods

Published on: April 24, 2020

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

Related Experiment Videos

Last Updated: Sep 17, 2025

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

A Whole Body Dosimetry Protocol for Peptide-Receptor Radionuclide Therapy PRRT: 2D Planar Image and Hybrid 2D+3D SPECT/CT Image Methods

A Whole Body Dosimetry Protocol for Peptide-Receptor Radionuclide Therapy PRRT: 2D Planar Image and Hybrid 2D+3D SPECT/CT Image Methods

Published on: April 24, 2020

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024